5/13/2020 8:09:30 AM
Lipocine : Treatment Potential Of LPCN 1144 Demonstrated In A Pre-Clinical NASH And Hepatic Fibrosis Model
5/7/2020 8:10:20 AM
Lipocine Q1 Net Loss $5.8 Mln Or $0.14/shr Vs. Net Loss $3.2 Mln Or $0.14/shr Last Year
5/5/2020 8:06:30 AM
Lipocine Says FDA Clears LPCN 1148 IND Application For Phase 2 Cirrhosis Trial
4/17/2020 8:08:00 AM
Lipocine Says FDA Denied Citizen Petition Filed By Clarus Therapeutics On October 2, 2019
3/26/2020 8:05:33 AM
Lipocine Reports Outcome Of Markman Hearing In Patent Infringement Suit Against Clarus
2/25/2020 8:33:19 AM
Lipocine Announces $6 Mln Registered Direct Offering Priced At-The-Market
2/24/2020 7:08:38 AM
Lipocine Announces Results Of Post Action Meeting For TLANDO NDA; Says Regulatory Path Forward For TLANDO Resubmission
11/11/2019 6:31:32 AM
Lipocine Receives Complete Response Letter For TLANDO From FDA
8/7/2019 8:08:40 AM
Lipocine Q2 Net Loss $3.4 Mln Or $0.14/shr Vs. Net Loss Of $3.3 Mln Or $0.15/shr Prior Year